Trials / Completed
CompletedNCT00055302
Arimidex in McCune Albright Syndrome
An Open-label Study Evaluating the Safety and Efficacy of Anastrozole™ (ARIMIDEX) in the Treatment of Precocious Puberty in Girls With McCune-Albright Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety and efficacy of anastrozole 1 mg given once daily in subjects with McCune-Albright Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arimidex 1 mg | Arimidex (anastrozole) 1mg once daily by mouth |
Timeline
- Start date
- 2002-08-01
- Primary completion
- 2006-02-01
- Completion
- 2015-08-01
- First posted
- 2003-02-26
- Last updated
- 2015-09-01
Locations
7 sites across 4 countries: France, Germany, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT00055302. Inclusion in this directory is not an endorsement.